Help us improve guidance content on our website. Complete our short survey.
Type
- ARTG (493)
- Cancellation by sponsor (327)
- Laboratory test report (151)
- Australian Public Assessment Report (AusPAR) (52)
- Prescription medicine registration (30)
- Section 14, TGO91 consent (21)
- Prescription medicine decision summary (13)
- Designation or determination (8)
- Cancellation or suspension (7)
- Prescription medicine evaluation (5)
Date
- 2023 (17)
- 2022 (25)
- 2021 (114)
- 2020 (181)
- 2019 (116)
- 2018 (112)
- 2017 (92)
- 2016 (16)
- 2015 (22)
- 2014 (23)
- 2013 (9)
- 2012 (9)
- 2011 (15)
- 2010 (29)
- 2009 (15)
- 2008 (7)
- 2007 (13)
- 2006 (12)
- 2005 (7)
- 2004 (8)
- 2003 (9)
- 2002 (13)
- 2001 (9)
- 2000 (22)
- 1999 (12)
- 1998 (12)
- 1997 (18)
- 1996 (10)
- 1995 (3)
- 1994 (36)
- 1993 (21)
- 1992 (9)
- 1991 (91)
Sponsor content
1107 result(s) found, displaying 1 to 10
- Australian Public Assessment Report (AusPAR)AusPAR: Prevenar 20AusPAR for Prevenar 20 (pneumococcal polysaccharide conjugate vaccine) for the prevention of pneumococcal disease caused by Streptococcus pneumoniae.
- ARTGDEPO-PROVERA medroxyprogesterone acetate 150 mg/1 mL suspension for injection pre-filled syringe (401610)Australian Register of Therapeutic Goods (ARTG) information for DEPO-PROVERA medroxyprogesterone acetate 150 mg/1 mL suspension for injection pre-filled syringe.
- May-2023Prescription medicine evaluationTALZENNA Pfizer Australia Pty LtdActive ingredient: talazoparib tosilate.
- May-2023Prescription medicine evaluationABRYSVO Pfizer Australia Pty LtdActive ingredient: recombinant respiratory syncytial virus pre-fusion F protein, water for injections.
- Designation or determinationNotice for elranatamab (Pfizer Australia Pty Ltd)Provisional determination
- Designation or determinationNotice for tozinameran and famtozinameran (Pfizer Australia Pty Ltd)Provisional determination
- Mar-2023Prescription medicine evaluationVELSIPITY Pfizer Australia Pty LtdActive ingredient: etrasimod arginine.
- Australian Public Assessment Report (AusPAR)AusPAR: Comirnaty Original / Omicron BA.4 5 COVID-19 vaccineAusPAR for Comirnaty Original/Omicron BA.4-5 COVID-19 vaccine (tozinameran and famtozinam) for prevention of COVID-19.
- Australian Public Assessment Report (AusPAR)AusPAR: NgenlaAusPAR for Ngenla (somatrogon) for treatment of paediatric patients with growth disturbance due to insufficient growth hormone.
- Prescription medicine decision summaryComirnaty Original/Omicron BA.4-5 COVID-19 vaccineComirnaty Original/Omicron BA.4-5 COVID-19 vaccine (tozinameran and famtozinameran) is approved to prevent coronavirus disease 2019.